Dergiler / Journal of Health Sciences and Medicine / 2026 / Volume: 9 Issue: 5

Impact of age on mortality in community-acquired pneumonia

Güzide Tomas(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İSTANBUL SULTAN ABDÜLHAMİD HAN SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0009-0007-8739-7969
Mustafa Düger(İSTANBUL MEDİPOL ÜNİVERSİTESİ)0000-0002-4091-6465
Merve Güleryüz Can(Menteşe Devlet Hastanesi)0000-0001-6162-8174
Şeyma Başlılar(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İSTANBUL SULTAN ABDÜLHAMİD HAN SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0000-0003-1495-6508
Sayfa
—
Yayın Tarihi
2026-09-19
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

These findings suggest that prognostic assessment in CAP should be guided by clinical severity and host vulnerability rather than chronological age alone.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aims: Community-acquired pneumonia (CAP) remains a major cause of hospitalization and mortality worldwide, particularly among older adults.
📊
Temel Bulgular & Veri:To evaluate the impact of age on 6-month mortality in hospitalized patients with CAP and to identify independent predictors of mortality.
💡
Sonuç & Katkı:These findings suggest that prognostic assessment in CAP should be guided by clinical severity and host vulnerability rather than chronological age alone.
🔬Tür:Research Article
📍Kapsam:2018 Verileri
⚙️Değişkenler:Community-acquired pneumonia · age · mortality

Abstract

Aims: Community-acquired pneumonia (CAP) remains a major cause of hospitalization and mortality worldwide, particularly among older adults. Although advanced age is commonly associated with adverse outcomes, its independent contribution to mortality remains uncertain. To evaluate the impact of age on 6-month mortality in hospitalized patients with CAP and to identify independent predictors of mortality. Methods: This retrospective single center cohort study included 613 patients aged 50 years and older who were hospitalized with CAP between January 2018 and January 2025. Patients were stratified into three age groups: 50-64 years (n=116), 65-79 years (n=280), and ≥80 years (n=217). Demographic characteristics, comorbidities, disease severity, microbiological findings, laboratory parameters, and clinical outcomes were compared among groups. Factors associated with 6-month mortality were evaluated using univariate and multivariable logistic regression analyses. Results: Older patients had a higher burden of comorbidities, poorer functional status, and higher CURB-65 scores. However, 6-month mortality rates did not differ significantly among age groups (5.2%, 5.7%, and 7.8%, respectively; p=0.532). In multivariable logistic regression analysis, immunosuppression (OR: 7.239, 95% CI: 1.894-27.676; p=0.004), high-risk CURB-65 classification (OR: 3.980, 95% CI: 1.235-12.827; p=0.021), and lower admission pH (OR: 0.161, 95% CI: 0.084-0.309; p<0.001) were independently associated with mortality. Age was not independently associated with 6-month mortality (OR: 1.004, 95% CI: 0.965-1.045; p=0.831). Conclusion: Although advanced age was associated with greater comorbidity burden and disease severity at presentation, it was not an independent predictor of 6-month mortality among hospitalized patients with CAP. Mortality was independently associated with immunosuppression, high-risk CURB-65 classification, and impaired acid base status at presentation. These findings suggest that prognostic assessment in CAP should be guided by clinical severity and host vulnerability rather than chronological age alone.

🔖

Bu Makaleye Atıf Yap

Tomas, G., Düger, M., Can, M. G., Başlılar, Ş. (2026). Impact of age on mortality in community-acquired pneumonia. Journal of Health Sciences and Medicine, Volume: 9 Issue: 5. https://doi.org/10.32322/jhsm.1952923

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (18)

  1. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200:7. doi: 10.1164/rccm.201908-1581ST
  2. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336(4):243-250. doi:10.1056/NEJM199701233360402
  3. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377-382. doi:10.1136/thorax.58.5.377
  4. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3). doi:10.1136/thx.2009.121434
  5. Launders N, Ryan D, Winchester CC, Skinner D, Konduru PR, Price DB. Management of community-acquired pneumonia: an observational study in UK primary care. Pragmat Obs Res. 2019;10:53-65. doi:10.2147/POR.S211198
  6. Martin-Loeches I, Torres A, Nagavci B, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 2023;49(6):615-632. doi:10.1007/s00134-023-07033-8
  7. van Daalen FV, Boersma WG, van de Garde EMW, et al. Management of community-acquired pneumonia in adults: practice guideline from the Dutch Working Party on Antibiotic Policy and Dutch Association of Chest Physicians. CMI Communications. 2026;3(3):105206. doi:10.1016/ j.cmicom.2026.105206
  8. Carmona C, Bewick T, Macduff N, Thomas A. Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management-summary of NICE guidance. BMJ. 2024;384. doi:10.1136/bmj.q339
  9. Gonçalves-Pereira J, Froes F, Pereira FG, Diniz A, Oliveira H, Mergulhão P. Community-acquired pneumonia mortality trends according to age and gender: 2009 to 2019. BMC Pulm Med. 2025;25(1):391. doi:10.1186/s12890-025-03875-8
  10. Cilloniz C, Ceccato A, San Jose A, Torres A. Clinical management of community acquired pneumonia in the elderly patient. Expert Rev Respir Med. 2016;10(11):1211-1220. doi:10.1080/17476348.2016.1240037
  11. Marrie TJ, Huang JQ. Low-risk patients admitted with community-acquired pneumonia. Am J Med. 2005;118(12):1357-1363. doi:10.1016/j.amjmed.2005.06.035
  12. Cillóniz C, Torres A, Niederman MS. Management of pneumonia in critically ill patients. BMJ. 2021;375. doi:10.1136/bmj-2021-065871
  13. Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. Lancet. 2015;386(9998):1097-1108. doi:10.1016/S0140-6736(15)60733-4
  14. Li S, Li L, Wang S, Wu H. Clinical characteristics and risk factors of hospital mortality in elderly patients with community-acquired pneumonia. Front Med (Lausanne). 2025;12:1512288. doi:10.3389/fmed. 2025.1512288
  15. Ramirez JA, Musher DM, Evans SE, et al. Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies. Chest. 2020;158(5):1896-1911. doi:10.1016/j.chest.2020.05.598
  16. Carella F, Aliberti S, Stainer A, Voza A, Blasi F. Long-term outcomes in severe community-acquired pneumonia. Semin Respir Crit Care Med. 2024;45(2):266-273. doi:10.1055/s-0044-1781426
  17. Cakir N, Gozke E, Ekinci SC, et al. Cytokines and other laboratory parameters of hospitalized COVID-19 patients that predict intensive care unit admission. Clin Lab. 2024;70:10. doi:10.7754/Clin.Lab.2024.240109
  18. Malézieux-Picard A, Azurmendi L, Pagano S, et al. Role of clinical characteristics and biomarkers at admission to predict one-year mortality in elderly patients with pneumonia. J Clin Med. 2022;11(1):105. doi:10.3390/jcm11010105